The research from the laboratory was presented at the second Drug Developers Summit "Sirius.Biotech"

As part of the special session "Study of Safety and Biomarkers of New Drugs," a report was given on "The Use of the 'Human-on-a-Chip' Platform in Drug Development"

Presentation by Evgeny Knyazev, Head of the Laboratory of Molecular Physiology, Faculty of Biology and Biotechnology, HSE University

E. Knyazev

Presentation by Evgeny Knyazev, Head of the Laboratory of Molecular Physiology, Faculty of Biology and Biotechnology, HSE University

E. Knyazev

---

From May 15-17, 2024, the federal territory of Sirius hosted the second Drug Developers Summit "Sirius.Biotech." Representatives from universities, academic institutes, and high-tech companies involved in drug development, as well as students and young scientists, were invited to the summit.

Within the special session "Study of Safety and Biomarkers of New Drugs," moderated by Dmitry Alekseevich Sychev, academician of the RAS, professor of the RAS, doctor of medical sciences, and rector of the Russian Medical Academy of Continuous Professional Education, a report was presented by E. Knyazev, M. Shkurnikov, A. Tonevitsky, and B. Alekseev: "The Use of the 'Human-on-a-Chip' Platform in Drug Development."

Evgeny Knyazev, head of the Laboratory of Molecular Physiology at the Faculty of Biology and Biotechnology of HSE University, presented the capabilities of the microfluidic platform Homunculus for studying drug permeability using intestine-on-a-chip and placenta-on-a-chip models, investigating drug metabolism with a liver-on-a-chip model, as well as the results of studies on tumor-on-a-chip and metastasis-on-a-chip.